




CORPORATE PRESENTATION

The right drugs for **everyone, everywhere**

A hyperlean, AI-native biopharma company
operating across Mexico, the US and Latin
America.

CORPORATE OVERVIEW · 2026



WHAT WE DO

One hyperlean, AI-native platform. **Built, proven, now expanding.**

We in-license and co-develop, then carry each molecule through registration, access and launch — at a fraction of the usual cost and time.

WHAT WE TAKE ON

01

Three asset classes

Biologics, biosimilars and complex generics where the need is real and the path to launch is credible.

HOW WE DO IT

02

In-licensing and co-dev

Partners manufacture; we own registration, access and launch.

WHY WE ARE FAST

03

AI-native, end-to-end

One platform runs screening, submissions and launch readiness — in parallel, not in sequence.

4–5 months

Program decision to submission, vs 12–18 industry

~4×

Asset-to-market pace vs industry

One team

Runs every signed molecule

Three years of proof that the model works.

Formation to first launch	4 yrs
Signed molecules	13
Regulatory submissions	11
COFEPRIS approvals secured	4
In biologics submissions, Mexico 2025	#1
International partnerships	8

FIRST SALE COMPLETED
Selling in market today

Mexico is our first proof of execution, not a pilot.

NEXT MILESTONE
First US anchor asset announced before the end of 2026. First Sale in the Central American Market in 2027

PIPELINE

13 signed molecules across four therapeutic areas.

In commercialisation Submitted to COFEPRIS Signed

RHEUMATOLOGY & BONE

ONCOLOGY & SUPPORTIVE CARE

CARDIO-METABOLIC

IMMUNOLOGY

Teriparatide

Hyaluronic acid 1%

Hyaluronic acid 1.5%

Hyaluronic acid 2%

Denosumab 60 mg

Bevacizumab

Pegfilgrastim

Denosumab 120 mg

Liraglutide

Sitagliptin / metformin

Metformin XR

Rosuvastatin / ezetimibe

Mycophenolic acid

+5 / year

Our goal is to add at least five new molecules to the pipeline every year.

OUR PARTNERS

International partners **already build with us.**



Innovent

FOSUN PHARMA
复星医药



KASHIV
BIOSCIENCES



dexa group

MBI
MAXIGEN BIOTECH INC.

High quality molecules, launched at **Saya speed.**

Top quality products, met by 4–5 months to submission and a Mexico-anchored commercial platform.

GET IN TOUCH

Adrián García · Co-Founder & CEO

EMAIL

adrian.garcia@saya.bio

WEB

saya.bio